Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 1,019 shares of the company's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the sale, the vice president owned 33,934 shares of the company's stock, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Price Performance
NYSE EW opened at $81.16 on Tuesday. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $81.59 and a 200 day simple moving average of $81.89. The company has a market cap of $46.79 billion, a P/E ratio of 44.35, a P/E/G ratio of 2.11 and a beta of 0.95. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the prior year, the company posted $0.59 earnings per share. Edwards Lifesciences's quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the stock. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Evercore reissued an "outperform" rating and issued a $94.00 price target on shares of Edwards Lifesciences in a report on Monday, January 5th. TD Cowen raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Friday, January 9th. Barclays reissued an "overweight" rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, Truist Financial set a $89.00 price target on shares of Edwards Lifesciences and gave the company a "hold" rating in a report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $95.96.
Read Our Latest Stock Analysis on EW
Hedge Funds Weigh In On Edwards Lifesciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Level Four Advisory Services LLC lifted its holdings in shares of Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock worth $257,000 after acquiring an additional 119 shares during the period. Colonial Trust Co SC lifted its holdings in shares of Edwards Lifesciences by 0.4% during the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock worth $2,504,000 after acquiring an additional 120 shares during the period. Evermay Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 4.0% during the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company's stock worth $282,000 after acquiring an additional 128 shares during the period. Rehmann Capital Advisory Group lifted its holdings in shares of Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after acquiring an additional 130 shares during the period. Finally, Howard Capital Management Inc. lifted its holdings in shares of Edwards Lifesciences by 3.3% during the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock worth $322,000 after acquiring an additional 132 shares during the period. 79.46% of the stock is owned by institutional investors.
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
